Boston, MA 03\/18\/2014 (wallstreetpr) – The short story is that early investors in Regado Biosciences Inc (NASDAQ:RGDO)<\/b> are working to register their shares with the Securities Exchange Commission (SEC). The long story is about what this means for you as a retail investor. We take a closer look into this development and its impact or indication on the stock.<\/p>\n
Shares of the company were up significantly in the last session, gaining 8.10 percent to $12.01. The heavy stock trading day saw shares touching lows of $11.12 and highs of $12.49 during the session, thus establishing a new one-year high at $12.49.<\/p>\n
The company conducted its IPO last August where a total of $43 million was raised.<\/p>\n
Early investors making interesting move<\/b><\/p>\n
The investors who are reported to have contact SEC to register their share are mainly private equity groups that invested in the company at the earlier opportunity. The shareholders are reportedly offering to register a combined amount of shares numbering 4 million at a price of $10.46. Once this registration is done, the investors will be able to sell their shares at the market price at the time of selling.<\/p>\n
The question that shouldn\u2019t go unanswered is why the early shareholders are interested in \u2018unlocking\u2019 their shares? Could it be that they have gotten wind of an upcoming windfall for which they are plotting to cash in on?<\/p>\n
Considering that Regado Biosciences Inc (NASDAQ:RGDO) is developing a product that many have said has the potential of selling well once it is brought to the market. It is easy to see why early investors would want to have their shares ready for trade so that they can cash in on the expected windfall.<\/p>\n
If that is the thesis, then you can also up your position in the stock now that the shares look discounted.<\/p>\n
The journey of drug stocks<\/b><\/p>\n
Regado Biosciences Inc (NASDAQ:RGDO) has been a source of losses before and after it went public. Yet, loss-making is very usual for drug companies given that they spend a lot of money in drug development. However, once they bring their products to the market as Regado is almost edging closer, the story will change almost instantly.<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 03\/18\/2014 (wallstreetpr) – The short story is that early investors in Regado Biosciences Inc (NASDAQ:RGDO) are working to register their shares with the […]<\/p>\n","protected":false},"author":12,"featured_media":17006,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[5055,5054],"stock_ticker":[],"class_list":["post-17478","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqrgdo","tag-regado-biosciences-inc-nasdaqrgdo","entry"],"acf":[],"yoast_head":"\n